Science News
from research organizations

TJP1 protein may identify multiple myeloma patients most likely to benefit from proteasome inhibitors

Date:
April 28, 2016
Source:
University of Texas M. D. Anderson Cancer Center
Summary:
A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study.
Share:
FULL STORY

A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study led by The University of Texas MD Anderson Cancer Center.

Multiple myeloma is a cancer that forms from white blood cells found in the bone marrow, normally vital to producing antibodies and maintaining a healthy immune system. It is the second most common type of blood cancer.

"Proteasome inhibitors form the cornerstone of our standard therapy for multiple myeloma. However, no biomarkers have been clinically validated that can identify patients most likely to respond to this treatment," said study lead Robert Orlowski, M.D., Ph.D., chair ad interim of Lymphoma/Myeloma. "Our findings provide a rationale for use of TJP1 as the first biomarker to select patients who are most and least likely to benefit from proteasome inhibitors."

The research team's findings are published in the April 28 online issue of Cancer Cell.

TJP1 has not previously been known to play any role as a mediator of proteasome inhibitor sensitivity in multiple myeloma. Orlowski's group showed that TJP1 modulated signaling through a pathway involving EGFR, JAK1, and STAT3. The study findings supported the hypothesis that plasma cells which express low TJP1 levels have both high EGFR/JAK1/STAT3 activity and proteasome content.

"Therefore, these plasma cells were resistant to proteasome inhibitors," said Orlowski. "Moreover, they demonstrated a previously unknown role for EGFR signaling in myeloma, and for STAT3 in controlling the level of proteasomes in cells, and therefore the cell's ability to break down proteins.

The team observed that patients whose myeloma cells expressed low TJP1 levels were significantly less likely to achieve a response or benefit from bortezomib.

"This study allows us to identify promising future directions to overcome proteasome inhibitor resistance in patients with high signaling through EGFR/JAK1/STAT3 pathway by offering combination therapies such as bortezomib with either the EGFR inhibitor erlotinib, or a JAK1 inhibitor such as ruxolitinib," said Orlowski.

The research was part of MD Anderson's SPORE in Multiple Myeloma, and also the Moon Shots Program aimed at accelerating the conversion of scientific discoveries into clinical advances and significantly reducing cancer deaths.


Story Source:

Materials provided by University of Texas M. D. Anderson Cancer Center. Note: Content may be edited for style and length.


Journal Reference:

  1. Xing-Ding Zhang et al. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell, April 2016 DOI: 10.1016/j.ccell.2016.03.026

Cite This Page:

University of Texas M. D. Anderson Cancer Center. "TJP1 protein may identify multiple myeloma patients most likely to benefit from proteasome inhibitors." ScienceDaily. ScienceDaily, 28 April 2016. <www.sciencedaily.com/releases/2016/04/160428132254.htm>.
University of Texas M. D. Anderson Cancer Center. (2016, April 28). TJP1 protein may identify multiple myeloma patients most likely to benefit from proteasome inhibitors. ScienceDaily. Retrieved May 26, 2017 from www.sciencedaily.com/releases/2016/04/160428132254.htm
University of Texas M. D. Anderson Cancer Center. "TJP1 protein may identify multiple myeloma patients most likely to benefit from proteasome inhibitors." ScienceDaily. www.sciencedaily.com/releases/2016/04/160428132254.htm (accessed May 26, 2017).

RELATED STORIES